SCHEMBL6476374

SCHEMBL6476374

COC(=O)c1cc2[nH]c(S)nc2cc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.42
FGFR1 P11362 1/20 0.41
SRC P12931 1/20 0.41
KDM4E B2RXH2 4/20 0.40
EGLN1 Q9GZT9 2/20 0.38
RHEB Q15382 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
HTT P42858 2/20 0.37
MAPK1 P28482 2/20 0.37
TSHR P16473 1/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DHODH Q02127 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9523299 0.84 RHEB (0.41) GAAKDM4ERHEBHTTMAPK1
SCHEMBL8316649 0.81 RHEB (0.41) GAAKDM4ERHEBHTTMAPK1
SCHEMBL211457 0.80 AMY1A (0.45) EGLN1PDE3BPDE3AKMT2A
SCHEMBL10834070 0.74 EGLN1 (0.47) GAAEGLN1PDE3BPDE3AHTT
SCHEMBL12100557 0.74 GAA (0.46) GAAFGFR1SRCKDM4ERHEB
SCHEMBL6217364 0.74 KDM4E (0.50) KDM4ERHEBHTTMAPK1ALDH1A1
SCHEMBL6217370 0.74 HTT (0.64) GAAKDM4ERHEBHTTMAPK1
SCHEMBL27707178 0.74 GAA (0.44) GAAFGFR1SRCKDM4EHTT
SCHEMBL7899516 0.72 GRIN2D (0.63) GAAKDM4EHTTPOLBALDH1A1
SCHEMBL9455942 0.72 AMY1A (0.47) KDM4EPOLBLMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US disclosed
US-5869513-A ANTIULCER AGENTS G. D. SEARLE & CO. (US) 1999-02-09 US disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO disclosed
EP-0204215-A1 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines G.D. Searle & Co. (US) 1986-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 GAA 160/4885FGFR1 4691/4885SRC 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.